ReviewJournal of personalized medicine2024
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review.
Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Association between the atherogenic index of plasma trajectory and risk of cardiovascular diseases among hypertensive patients: a prospective cohort study.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Interactive Effects of HDL Cholesterol and hs-CRP in Relation to Cardiometabolic Risk Clustering Among Middle-Aged Adults.Medicina (Kaunas, Lithuania) · 2026Article
- Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation.ACR open rheumatology · 2026Review
- Decreased HDL-C in hidradenitis suppurativa: association with systemic inflammatory phenotype and implications for risk stratification.Lipids in health and disease · 2026Article
- Plasma Macrophage Migration Inhibitory Factor as a Biomarker of Thromboinflammatory Dysregulation in Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis.Archives of rheumatology · 2026Article
- Chronic, Environmentally Relevant PMThe Kaohsiung journal of medical sciences · 2026Article
- Serum uric acid-to-HDL-C ratio as an independent predictor of metabolic syndrome in the elderly: diagnostic model optimization and inflammatory mechanism insights.BMC geriatrics · 2026Article
- Article
- AnGenes · 2026Article
- Homocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles.Bioscience reports · 2026Article
- Cross-sectional association of the uric acid-to-HDL cholesterol ratio with diabetic kidney disease in patients with type 2 diabetes.Frontiers in nutrition · 2026Article
- Latent profile analysis of health status and influencing factors among patients with coronary heart disease based on patient-reported outcomes.Frontiers in cardiovascular medicine · 2026Article
- Age-associated chemokine receptor expression profiles in human peripheral blood monocyte subsets predict cardiovascular disease risk.Frontiers in immunology · 2026Article
- Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and osteoporotic fracture.Frontiers in medicine · 2026Article
- A Nomogram for Predicting 5-Year Risk of New-Onset Type 2 Diabetes in Patients with COPD: A Two-Center Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies.Frontiers in cardiovascular medicine · 2026Review
- Association of HDL-C levels with all-cause mortality in ACS patients after PCI: a multicenter prospective cohort study.Heart and vessels · 2025Article
- Is Crocin Effective in Modulating Blood Lipid Levels? An Updated Systematic Review and Meta-Analysis with Dose- and Time-Response Assessments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of SCORE, SCORE2 and Framingham Risk Score-Based Methods for Vascular Age Calculation.Journal of clinical medicine · 2025Article
- Comparison of Risk Stratification Tools for Atherosclerotic Cardiovascular Disease and Cardiovascular-Kidney-Metabolic Syndrome in Primary Care.Medical sciences (Basel, Switzerland) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoprotein (HDL) cholesterol is traditionally viewed as protective against cardiovascular disease (CVD). However, emerging evidence reveals that dysfunctional HDL, characterized by impaired reverse cholesterol transport (RCT), reduced anti-inflammatory and antioxidant activities and increased endothelial dysfunction, which can contribute to coronary artery disease (CAD). Dysfunctional HDL, resulting from oxidative modifications of Apolipoprotein A-1 (Apo A-1) and enzyme inactivation, fails to effectively remove cholesterol from peripheral tissues and may promote inflammation and atherosclerosis. Genetic mutations affecting HDL metabolism further complicate its role in cardiovascular health. Studies have shown that conventional therapies aimed at raising HDL-C levels do not necessarily reduce cardiovascular events, highlighting the need for new approaches that improve HDL functionality. Therapeutic strategies such as Apo A-1 mimetic peptides, reconstituted HDL infusions, and drugs targeting specific HDL metabolic pathways are being explored. Additionally, weight loss, statin therapy, and niacin have shown potential in enhancing HDL function. The pathophysiology of dysfunctional HDL involves complex mechanisms, including oxidative stress, inflammation, and genetic mutations, which alter its structure and function, diminishing its cardioprotective effects. New functional assays, such as the cholesterol efflux capacity (CEC) and HDL inflammatory index, provide more accurate predictions of cardiovascular risk by assessing HDL quality rather than quantity. As research progresses, the focus is shifting towards therapeutic strategies that enhance HDL function and address the root causes of its dysfunction, offering a more effective approach to reducing cardiovascular risk and preventing CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.